A Phase 2 interventional study of aflibercept injection (VEGF Trap-Eye, BAY86-5321) and aflibercept injection (VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 18 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-03-01.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 67 studies testing aflibercept in Macular Degeneration, this one is the 20th largest by enrollment, is one of 2 that started in 2006, is one of 7 in phase 2, and was the 1st registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Honghua Yu,MD
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 28
First in 2005; this study’s year is marked. 2 started in 2006.
This study's enrollment of 159 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 54 across the 67 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 67 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
17 studies in Macular Degeneration by Regeneron Pharmaceuticals: 2 open now, 3 under way, 2 of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 17 studies in Macular Degeneration by Regeneron Pharmaceuticals, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 2, and was the 1st registered.
Regeneron Pharmaceuticals’s Macular Degeneration studies by the year they started, since 2005.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 67 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Regeneron Pharmaceuticals’s 17 in Macular Degeneration:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD.
The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.
This is a double masked, prospective, randomized study in which five groups of approximately 30 patients meeting the eligibility criteria will be randomly assigned in a balanced ratio to receive a series of intravitreal (IVT) injections of VEGF Trap into the study eye at 4- or 12 -week intervals over a 12-week period.
After Week 12, patients will be evaluated every 4 weeks. Patients will remain on study or may be eligible to enter a long-term extension study, in which they will continue to receive VEGF Trap.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior treatment with the following in the study eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
Also known as: VEGF Trap-Eye, BAY86-5321
Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
Also known as: VEGF Trap-Eye, BAY86-5321
Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
Also known as: VEGF Trap-Eye, BAY86-5321
Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
Also known as: VEGF Trap-Eye, BAY86-5321
Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
Also known as: VEGF Trap-Eye, BAY86-5321
Mean Change of CR/LT From Baseline at Week 12
CR/LT measured in micrometers (µm); lower individual values represent better outcomes.
Time frame: Baseline and at Week 12
Mean Percent Change of CR/LT From Baseline at Week 12
CR/LT measured in micrometers (µm); a more negative percentage represents a better outcome
Time frame: Baseline and at Week 12
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning
Time frame: Baseline and at week 12
Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning
Time frame: At Week 12
The study was conducted at 29 study sites in the United States. Recruitment period: May 2006 to April 2007.
| Milestone | Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4 | Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12 | Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4 | Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12 | Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12 |
|---|---|---|---|---|---|
| Started | 32 | 32 | 32 | 32 | 31 |
| Participants received treatment (saf) | 32 | 32 | 31 | 31 | 31 |
| Completed | 26 | 26 | 29 | 27 | 26 |
| Not completed | 6 | 6 | 3 | 5 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Decision by the sponsor | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Other | 1 | 2 | 1 | 1 | 1 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 | 3 | 1 |
CR/LT measured in micrometers (µm); lower individual values represent better outcomes.
| μm | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Mean Change of CR/LT From Baseline at Week 12 | -153.5 ± 113.30 | -75.6 ± 110.64 | -169.2 ± 138.46 | -56.3 ± 133.05 | -139.8 ± 228.59 | -118.8 ± 155.31 |
CR/LT measured in micrometers (µm); a more negative percentage represents a better outcome
| percent change | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Mean Percent Change of CR/LT From Baseline at Week 12 | -32.4 ± 18.92 | -15.2 ± 22.52 | -33.2 ± 19.56 | -10.3 ± 25.49 | -21.1 ± 31.56 | -22.5 ± 25.41 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning
| letters read | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12 | 8.8 ± 9.20 | 3.8 ± 11.55 | 8.3 ± 10.14 | 5.2 ± 8.46 | 2.6 ± 8.72 | 5.7 ± 9.87 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning
| percentage of participants | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12 | 18.8 ± 0 | 21.9 ± 0 | 25.8 ± 0 | 16.1 ± 0 | 9.7 ± 0 | 18.5 ± 0 |
CR/LT measured in micrometers (µm); lower individual values represent better outcomes
| µm | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Mean Change of CR/LT From Baseline at Week 16 | -163.3 ± 108.13 | -139.6 ± 126.41 | -182.7 ± 146.75 | -107.4 ± 112.22 | -208.6 ± 202.07 | -160.2 ± 145.34 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning
| letters read | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Mean Change in BCVA as Measured by ETDRS From Baseline at Week 16 | 9.3 ± 9.92 | 5.6 ± 12.24 | 10.0 ± 9.76 | 4.3 ± 10.01 | 3.9 ± 9.92 | 6.6 ± 10.60 |
Collected over Adverse events (AEs) considered related to study treatment were followed until resolution or until the event was considered chronic or stable.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept Injection 0.5mg q4 | — | — | — |
| Aflibercept Injection 0.5mg q12 | — | — | — |
| Aflibercept Injection 2.0mg q4 | — | — | — |
| Aflibercept Injection 2.0mg q12 | — | — | — |
| Aflibercept Injection 4.0mg q12 | — | — | — |
| Event | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 |
|---|---|---|---|---|---|
| CARDIAC FAILURE CONGESTIVECardiac disorders | 1/32 | 0/32 | 2/31 | 0/31 | 0/31 |
| CORONARY ARTERY DISEASECardiac disorders | 0/32 | 0/32 | 2/31 | 0/31 | 0/31 |
| PNEUMONIAInfections and infestations | 2/32 | 0/32 | 2/31 | 0/31 | 0/31 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/32 | 0/32 | 1/31 | 0/31 | 0/31 |
| SPINAL OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/32 | 0/32 | 0/31 | 1/31 | 0/31 |
| METASTASES TO LUNGNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 0/32 | 0/31 | 1/31 | 0/31 |
| PANCREATIC CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 0/32 | 1/31 | 0/31 | 0/31 |
| SQUAMOUS CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 0/32 | 1/31 | 0/31 | 0/31 |
| THYROID NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 0/32 | 0/31 | 1/31 | 0/31 |
| TRANSITIONAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 0/32 | 0/31 | 1/31 | 0/31 |
| Event | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 |
|---|---|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/32 | 1/32 | 2/31 | 6/31 | 3/31 |
| URINARY TRACT INFECTIONInfections and infestations | 1/32 | 3/32 | 6/31 | 1/31 | 2/31 |
| HYPERTENSIONVascular disorders | 6/32 | 1/32 | 2/31 | 0/31 | 3/31 |
| CONSTIPATIONGastrointestinal disorders | 5/32 | 1/32 | 0/31 | 0/31 | 1/31 |
| BRONCHITISInfections and infestations | 5/32 | 2/32 | 1/31 | 1/31 | 3/31 |
| EYE IRRITATIONEye disorders | 5/32 | 0/32 | 1/31 | 0/31 | 1/31 |
| EYE PAINEye disorders | 5/32 | 2/32 | 4/31 | 1/31 | 3/31 |
| VISUAL ACUITY REDUCEDEye disorders | 1/32 | 1/32 | 4/31 | 1/31 | 1/31 |
| VITREOUS DETACHMENTEye disorders | 4/32 | 1/32 | 2/31 | 3/31 | 4/31 |
| SEASONAL ALLERGYImmune system disorders | 4/32 | 2/32 | 0/31 | 0/31 | 1/31 |
| Age Continuous(years) | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Mean | 79.6 ± 7.56 | 78.5 ± 10.12 | 74.9 ± 7.63 | 79.6 ± 8.91 | 78.3 ± 5.97 | 78.2 ± 8.25 |
| Sex: Female, Male(Participants) | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Female | 17 ± 0 | 25 ± 0 | 20 ± 0 | 16 ± 0 | 20 ± 0 | 98 |
| Male | 15 ± 0 | 7 ± 0 | 11 ± 0 | 15 ± 0 | 11 ± 0 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 ± 0 | 1 ± 0 | 2 ± 0 | 1 ± 0 | 0 ± 0 | 4 |
| Not Hispanic or Latino | 32 ± 0 | 31 ± 0 | 29 ± 0 | 30 ± 0 | 31 ± 0 | 153 |
| Unknown or Not Reported | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 |
| Race (NIH/OMB)(Participants) | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 ± 0 | 0 ± 0 | 1 ± 0 | 0 ± 0 | 0 ± 0 | 1 |
| Asian | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 |
| Black or African American | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 |
| White | 32 ± 0 | 32 ± 0 | 30 ± 0 | 31 ± 0 | 31 ± 0 | 156 |
| More than one race | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 |
| Unknown or Not Reported | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 |
| Central Retinal/Lesion Thickness (CR/LT)(µm) | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Mean | 442.2 ± 109.81 | 442.6 ± 136.60 | 453.3 ± 143.93 | 447.0 ± 119.11 | 497.5 ± 191.17 | 456.4 ± 142.41 |
| Best Corrected Visual Acuity (BCVA)(letters read) | Aflibercept Injection 0.5mg q4 | Aflibercept Injection 0.5mg q12 | Aflibercept Injection 2.0mg q4 | Aflibercept Injection 2.0mg q12 | Aflibercept Injection 4.0mg q12 | Total |
|---|---|---|---|---|---|---|
| Mean | 54.1 ± 13.77 | 55.6 ± 11.75 | 57.9 ± 12.02 | 57.2 ± 10.47 | 53.0 ± 14.52 | 55.5 ± 12.57 |
The record gives a start of Apr 2006, a primary completion of Jun 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 3 years 9 months after primary completion. A results delay was requested in Nov 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept